Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS cardiologists and surgeons give children a beating heart
2015-04-23

Photo: René-Jean van der Berg

A team from the University of the Free State School for Medicine work daily unremittingly to save the lives of young children who have been born with heart defects by carrying out highly specialised interventions and operations on them. These operations, which are nowadays performed more and more frequently by cardiologists from the UFS School of Medicine, place the UFS on a similar footing to world-class cardiology and cardio-thoracic units.

One of the children is seven-month-old Montsheng Ketso who recently underwent a major heart operation to keep the left ventricle of her heart going artificially.

Montsheng was born with a rare, serious defect of the coronary artery, preventing the left ventricle from receiving enough blood to pump to the rest of the body.

This means that the heart muscle can suffer damage because these children essentially experience a heart attack at a very young age.

In a healthy heart, the left ventricle receives oxygenated blood from the left atrium. Then the left ventricle pumps this oxygen-rich blood to the aorta whence it flows to the rest of the body. The heart muscle normally receives blood supply from the oxygenated aorta blood, which in this case cannot happen.

Photo: René-Jean van der Berg

“She was very ill. I thought my baby was going to die,” says Mrs Bonizele Ketso, Montsheng’s mother.

She says that Montsheng became sick early in February, and she thought initially it was a tight chest or a cold. After a doctor examined and treated her baby, Montsheng still remained constantly ill, so the doctor referred her to Prof Stephen Brown, paediatric cardiologist at the UFS and attached to Universitas Hospital.

Here, Prof Brown immediately got his skilled team together as quickly as possible to diagnose the condition in order to operate on Montsheng.

During the operation, the blood flow was restored, but since Montsheng’s heart muscle was seriously damaged, the heart was unable to contract at the end of the operation. Then she was coupled to a heart-lung machine to allow the heart to rest and give the heart muscle chance to recover. The entire team of technologists and the dedicated anaesthetist, Dr Edwin Turton, kept a vigil day and night for several days.

Prof Francis Smit, chief specialist at the UFS Department of Cardiothoracic Surgery, explains that without this operation Montsheng would not have been able to celebrate her first birthday.

“After the surgery, these children can reach adulthood without further operations. Within two to three months after the operation, she will have a normal active life, although for about six months she will still use medication. Thereafter, she will be tiptop and shortly learn to crawl and walk.”

Mrs Ketso is looking forward enormously to seeing her daughter stand up and take her first steps. A dream which she thought would never come true.    

“Write there that I really love these doctors.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept